122 related articles for article (PubMed ID: 29415128)
1. Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries.
Oskay-Özcelik G; Alavi S; Richter R; Keller M; Chekerov R; Cecere SC; Cormio G; Joly F; Kurtz JE; du Bois A; Maciejewski M; Jedryka M; Vergote I; Van Nieuwenhuysen E; Casado A; Mendiola C; Achimas-Cadariu P; Vlad C; Reimer D; Zeimet AG; Friedlander M; Sehouli J
Ann Oncol; 2018 Apr; 29(4):910-916. PubMed ID: 29415128
[TBL] [Abstract][Full Text] [Related]
2. Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV).
Rohr I; Alavi S; Richter R; Keller M; Chekerov R; Oskay-Özcelik G; Heinrich M; Taskiran C; Joly F; Berger R; du Bois A; Gornjec A; Vergote I; Achimas-Cadariu P; Lorusso D; Maenpaa J; Sehouli J
Int J Gynecol Cancer; 2020 Apr; 30(4):509-514. PubMed ID: 32139438
[TBL] [Abstract][Full Text] [Related]
3. Expectations and perspectives of ovarian cancer patients about cancer management in Romania. The international NOGGO-ENGOT trial: EXPRESSION III.
Achimaş-Cadariu P; Iancu M; Kubelac P; Pop F; Braicu I; Vlad C; Oskay-Özcelik G; Sehouli J
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27507600
[TBL] [Abstract][Full Text] [Related]
4. Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany.
Dimitrova D; Naghavi B; Richter R; Nasser S; Chekerov R; Braicu EI; David M; Blohmer J; Inci G; Torsten U; Oskay-Özcelik G; Blau I; Fersis N; Holzgreve A; Keil E; Keller M; Keilholz U; Sehouli J
BMC Cancer; 2021 Sep; 21(1):1018. PubMed ID: 34511112
[TBL] [Abstract][Full Text] [Related]
5. [Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].
Lorcet M; Lortholary A; Kurtz JE; Berton-Rigaud D; Fabbro M; De La Motte Rouge T; Kaminsky-Forrett MC; Floquet A; Freyer G; Combe P; Dohollou N; Kalbacher E; Despax R; Largillier R; Hardy Bessard AC; Gane N; Sehouli J; Oskay-Oezcelik G; Licaj I; Ray-Coquard I; Joly Lobbedez F
Bull Cancer; 2018 May; 105(5):465-474. PubMed ID: 29544693
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients.
Oskay-Ozcelik G; Lehmacher W; Könsgen D; Christ H; Kaufmann M; Lichtenegger W; Bamberg M; Wallwiener D; Overkamp F; Diedrich K; von Minckwitz G; Höffken K; Seeber S; Mirz R; Sehouli J
Ann Oncol; 2007 Mar; 18(3):479-84. PubMed ID: 17272832
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
8. Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument.
Elit LM; Levine MN; Gafni A; Whelan TJ; Doig G; Streiner DL; Rosen B
Gynecol Oncol; 1996 Sep; 62(3):329-35. PubMed ID: 8812525
[TBL] [Abstract][Full Text] [Related]
9. [Expectations of patients with ovarian cancer. Results of the European investigation EXPRESSION III in French patients from GINECO group].
De Cock L; Kieffer A; Kurtz JE; Joly F; Weber B
Bull Cancer; 2015 Mar; 102(3):217-25. PubMed ID: 25749410
[TBL] [Abstract][Full Text] [Related]
10. What Do Ovarian Cancer Patients Expect From Treatment?: Perspectives From an Online Patient Community.
Simacek K; Raja P; Chiauzzi E; Eek D; Halling K
Cancer Nurs; 2017; 40(5):E17-E27. PubMed ID: 27454765
[TBL] [Abstract][Full Text] [Related]
11. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
Piccirillo MC; Scambia G; Bologna A; Signoriello S; Vergote I; Baumann K; Lorusso D; Murgia V; Sorio R; Ferrandina G; Sacco C; Cormio G; Breda E; Cinieri S; Natale D; Mangili G; Pisano C; Cecere SC; Di Napoli M; Salutari V; Raspagliesi F; Arenare L; Bergamini A; Bryce J; Daniele G; Gallo C; Pignata S; Perrone F
Ann Oncol; 2018 May; 29(5):1189-1194. PubMed ID: 29462248
[TBL] [Abstract][Full Text] [Related]
12. Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors-Results of Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey.
Woopen H; Keller M; Zocholl D; Mittelstadt S; Barretina-Ginesta MP; Heinzelmann-Schwarz V; Lafleur J; Kocián R; Baum J; Krabisch P; Achimas-Cadariu P; Vardar MA; Vergote I; Nasser S; Link T; Gil-Martin M; Zwimpfer TA; Leitner K; Jedryka M; Boxler T; Braicu EI; Sehouli J
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001688
[TBL] [Abstract][Full Text] [Related]
13. Development of a decision aid for primary treatment of patients with advanced-stage ovarian cancer.
den Ouden JE; The R; Myren BJ; Boll D; Driel WJV; Lalisang RI; Kruitwagen RF; van Altena AM
Int J Gynecol Cancer; 2020 Jun; 30(6):837-844. PubMed ID: 32276940
[TBL] [Abstract][Full Text] [Related]
14. The choice is yours? How women with ovarian cancer make sense of treatment choices.
Ziebland S; Evans J; McPherson A
Patient Educ Couns; 2006 Sep; 62(3):361-7. PubMed ID: 16876377
[TBL] [Abstract][Full Text] [Related]
15. Canadian women's perspectives on ovarian cancer.
Fitch MI; Gray RE; DePetrillo D; Franssen E; Howell D
Cancer Prev Control; 1999 Feb; 3(1):52-60. PubMed ID: 10474753
[TBL] [Abstract][Full Text] [Related]
16. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?
Sun CC; Bodurka DC; Donato ML; Rubenstein EB; Borden CL; Basen-Engquist K; Munsell MF; Kavanagh JJ; Gershenson DM
Gynecol Oncol; 2002 Oct; 87(1):118-28. PubMed ID: 12468352
[TBL] [Abstract][Full Text] [Related]
17. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.
Doyle C; Crump M; Pintilie M; Oza AM
J Clin Oncol; 2001 Mar; 19(5):1266-74. PubMed ID: 11230467
[TBL] [Abstract][Full Text] [Related]
18. Changes in supportive care needs after first-line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needs.
Beesley VL; Price MA; Webb PM; O'Rourke P; Marquart L; ; ; Butow PN
Psychooncology; 2013 Jul; 22(7):1565-71. PubMed ID: 22936668
[TBL] [Abstract][Full Text] [Related]
19. A study of symptoms described by ovarian cancer survivors.
Stavraka C; Ford A; Ghaem-Maghami S; Crook T; Agarwal R; Gabra H; Blagden S
Gynecol Oncol; 2012 Apr; 125(1):59-64. PubMed ID: 22155797
[TBL] [Abstract][Full Text] [Related]
20. OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.
Webber K; Carolus E; Mileshkin L; Sommeijer D; McAlpine J; Bladgen S; Coleman RL; Herzog TJ; Sehouli J; Nasser S; Inci G; Friedlander M
Gynecol Oncol; 2019 Oct; 155(1):126-134. PubMed ID: 31416612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
